Literature DB >> 10899961

Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease.

C Iannicola1, S Moreno, S Oliverio, R Nardacci, A Ciofi-Luzzatto, M Piacentini.   

Abstract

Several mouse models for Huntington's disease (HD) have been produced to date. Based on differences in strain, promoter, construct, and number of glutamines, these models have provided a broad spectrum of neurological symptoms, ranging from simple increases in aggressiveness with no signs of neuropathology, to tremors and seizures in absence of degeneration, to neurological symptoms in the presence of gliosis and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling) positivity, and finally to selective striatal damage associated with electrophysiological and behavioral abnormalities. We decided to analyze the morphology of striatum and hippocampus from a mouse transgenic line obtained by microinjection of exon 1 from the HD gene after introduction of a very high number of CAG repeat units. We found a massive darkening and compacting of striatal and hippocampal neurons in affected mice, associated with a lower degree of more classical apoptotic cell condensation. We then explored whether this morphology could be explained with alterations in gene expression by hybridizing normal and affected total brain RNA to a panel of 588 known mouse cDNAs. We show that some genes are significantly and consistently up-regulated and that others are down-regulated in the affected brains. Here we discuss the possible significance of these alterations in neuronal morphology and gene expression.

Entities:  

Mesh:

Year:  2000        PMID: 10899961     DOI: 10.1046/j.1471-4159.2000.0750830.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

1.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

2.  Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.

Authors:  Manisha Aggarwal; Wenzhen Duan; Zhipeng Hou; Neal Rakesh; Qi Peng; Christopher A Ross; Michael I Miller; Susumu Mori; Jiangyang Zhang
Journal:  Neuroimage       Date:  2012-02-09       Impact factor: 6.556

Review 3.  Misfolded proteins, endoplasmic reticulum stress and neurodegeneration.

Authors:  Rammohan V Rao; Dale E Bredesen
Journal:  Curr Opin Cell Biol       Date:  2004-12       Impact factor: 8.382

Review 4.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

Review 5.  Transcriptional signatures in Huntington's disease.

Authors:  Jang-Ho J Cha
Journal:  Prog Neurobiol       Date:  2007-04-01       Impact factor: 11.685

6.  Astrocyte-Dependent Vulnerability to Excitotoxicity in Spermine Oxidase-Overexpressing Mouse.

Authors:  Chiara Cervetto; Laura Vergani; Mario Passalacqua; Milena Ragazzoni; Arianna Venturini; Francesco Cecconi; Nicola Berretta; Nicola Mercuri; Marcello D'Amelio; Guido Maura; Paolo Mariottini; Adriana Voci; Manuela Marcoli; Manuela Cervelli
Journal:  Neuromolecular Med       Date:  2015-11-03       Impact factor: 3.843

7.  Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

Authors:  Zhao-Xue Yu; Shi-Hua Li; Joy Evans; Ajay Pillarisetti; He Li; Xiao-Jiang Li
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

8.  A New Transgenic Mouse Model for Studying the Neurotoxicity of Spermine Oxidase Dosage in the Response to Excitotoxic Injury.

Authors:  Manuela Cervelli; Gabriella Bellavia; Marcello D'Amelio; Virve Cavallucci; Sandra Moreno; Joachim Berger; Roberta Nardacci; Manuela Marcoli; Guido Maura; Mauro Piacentini; Roberto Amendola; Francesco Cecconi; Paolo Mariottini
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

Review 9.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

10.  Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse.

Authors:  Jan Fahrenkrug; Natalija Popovic; Birgitte Georg; Patrik Brundin; Jens Hannibal
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.